Dermata Therapeutics

Company snapshot

Dermata Therapeutics, Inc. (Nasdaq: DRMA) is a science-driven leader in dermatologic solutions. Tome skincare will launch mid-2026. Visit tomeskincare.com for more information. Dermata is headquartered in San Diego, California. For more information, please visit http://www.dermatarx.com/.

• 4 active pipeline program(s) linked via ClinicalTrials.gov.
• 30 US patent(s) indexed to this assignee profile.
• 4 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Dermata Therapeutics. Not investment advice.

• Peer + 0 momentum

  VYNE Therapeutics

  TA overlap score 26

• Peer + 0 momentum

  UAS Pharmaceuticals Pty

  TA overlap score 20.8

Recent activity

Latest pipeline, patent, and corporate events for Dermata Therapeutics.

1. Jun 8, 2026 Clinical update

   Topical Powder — Phase 2

2. May 23, 2026 Clinical update

   DMT310 — Phase 3

3. May 23, 2026 Clinical update

   DMT210 Topical Gel — Phase 2

4. May 23, 2026 Clinical update

   DMT210 Topical Gel 5% — Phase 2

5. Jan 28, 2025 Patent grant

   Compositions and methods for the treatment of skin conditions

View all clinical trial activity →

• What is Dermata Therapeutics?

  Dermata Therapeutics is a pharma organization headquartered in San Diego, USA. It trades on NYSE under ticker DRMA. Primary therapeutic focus areas include Acne Rosacea, Atopic Dermatitis, Acne Vulgaris. NovaPharmaNews links 4 clinical program(s), 0 drug profile(s), and 30 patent

• Is Dermata Therapeutics publicly traded?

  Yes. Dermata Therapeutics is listed with ticker DRMA on NYSE per SEC EDGAR records linked on this profile.

• What drugs does Dermata Therapeutics develop or market?

  We link 2 drug profile(s) where Dermata Therapeutics is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/dermata-therapeutics#company-drugs.

• What are the latest developments for Dermata Therapeutics?

  In the last 12 months our linked public records show 4 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Dermata Therapeutics focus on?

  Dermata Therapeutics focuses on Acne Rosacea, Atopic Dermatitis, Acne Vulgaris based on our analysis of their pipeline programs and drug development activities.